Literature DB >> 23962073

Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia.

Qian Liu1, Mangju Wang, Yang Hu, Haizhou Xing, Xue Chen, Ying Zhang, Ping Zhu.   

Abstract

In this study we investigated the significance of CD71 (transferrin receptor 1, TfR-1) as a flow cytometric marker in the diagnosis of acute leukemia (AL). A total of 105 patients with AL were enrolled. Poorly differentiated acute myeloid leukemias (AMLs) (including minimally differentiated AML, AML without maturation, AML with maturation, acute myelomonocytic leukemia) tended to express high levels of CD71 on leukemic cells, while partially differentiated AML (including acute promyelocytic leukemia and acute monocytic leukemia) often expressed low levels of CD71 on leukemic cells (p < 0.05, compared to poorly differentiated AML). B-cell acute lymphoblastic leukemia (B-ALL) expressed low levels of CD71 on leukemic cells, significantly lower than AML, mixed phenotype acute leukemia (MPAL) and normal bone marrow blasts (p < 0.05). In the seven cases of acute erythroid leukemia (AEL), leukemic cells rarely expressed CD71, with the mean CD71 expression level significantly lower than that of acute megakaryocytic leukemia (p < 0.05), and also lower than that of poorly differentiated AML and normal blasts but without statistical significance. CD71 may not be a specific marker for AEL leukemic cells. During the process from myeloid dysplasia to apparent leukemic cells, both CD71 and CD34 gradually increased. Consequently, the presence of leukemic cell subsets with variable levels of CD71 and CD34 may be useful for understanding the dynamic processes involved in the clonal development seen in leukemias.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23962073     DOI: 10.3109/10428194.2013.819100

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  11 in total

1.  Flow cytometric single cell analysis reveals heterogeneity between adipose depots.

Authors:  Badwi B Boumelhem; Stephen J Assinder; Kim S Bell-Anderson; Stuart T Fraser
Journal:  Adipocyte       Date:  2017-04-14       Impact factor: 4.534

2.  Development of Light-Activated CRISPR Using Guide RNAs with Photocleavable Protectors.

Authors:  Piyush K Jain; Vyas Ramanan; Arnout G Schepers; Nisha S Dalvie; Apekshya Panda; Heather E Fleming; Sangeeta N Bhatia
Journal:  Angew Chem Int Ed Engl       Date:  2016-08-24       Impact factor: 15.336

3.  Comprehensive Analysis of a Ferroptosis Pattern and Associated Prognostic Signature in Acute Myeloid Leukemia.

Authors:  Zelong Cui; Yue Fu; Zongcheng Yang; Zhenxing Gao; Huimin Feng; Minran Zhou; Lu Zhang; Chunyan Chen
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

Review 4.  Transferrin receptor 1 in cancer: a new sight for cancer therapy.

Authors:  Ying Shen; Xin Li; Dandan Dong; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

5.  Massively parallel digital transcriptional profiling of single cells.

Authors:  Grace X Y Zheng; Jessica M Terry; Phillip Belgrader; Paul Ryvkin; Zachary W Bent; Ryan Wilson; Solongo B Ziraldo; Tobias D Wheeler; Geoff P McDermott; Junjie Zhu; Mark T Gregory; Joe Shuga; Luz Montesclaros; Jason G Underwood; Donald A Masquelier; Stefanie Y Nishimura; Michael Schnall-Levin; Paul W Wyatt; Christopher M Hindson; Rajiv Bharadwaj; Alexander Wong; Kevin D Ness; Lan W Beppu; H Joachim Deeg; Christopher McFarland; Keith R Loeb; William J Valente; Nolan G Ericson; Emily A Stevens; Jerald P Radich; Tarjei S Mikkelsen; Benjamin J Hindson; Jason H Bielas
Journal:  Nat Commun       Date:  2017-01-16       Impact factor: 14.919

6.  CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.

Authors:  Niklas Landberg; Sofia von Palffy; Maria Askmyr; Henrik Lilljebjörn; Carl Sandén; Marianne Rissler; Satu Mustjoki; Henrik Hjorth-Hansen; Johan Richter; Helena Ågerstam; Marcus Järås; Thoas Fioretos
Journal:  Haematologica       Date:  2017-12-28       Impact factor: 9.941

7.  Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.

Authors:  Maura Gasparetto; Shanshan Pei; Mohammad Minhajuddin; Nabilah Khan; Daniel A Pollyea; Jason R Myers; John M Ashton; Michael W Becker; Vasilis Vasiliou; Keith R Humphries; Craig T Jordan; Clayton A Smith
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

8.  miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFβ signaling.

Authors:  Jeffrey Lam; Marion van den Bosch; Joanna Wegrzyn; Jeremy Parker; Rawa Ibrahim; Kate Slowski; Linda Chang; Sergio Martinez-Høyer; Gianluigi Condorelli; Mark Boldin; Yu Deng; Patricia Umlandt; Megan Fuller; Aly Karsan
Journal:  Nat Commun       Date:  2018-06-20       Impact factor: 14.919

9.  Plasmablastic Lymphoma, a Rare Entity in Bone Marrow with Unusual Immunophenotype and Challenging Differential Diagnosis.

Authors:  Majd Al Shaarani; Rodney E Shackelford; Samip R Master; Glenn M Mills; Yasir AlZubaidi; Ahmed Mamilly; Eric X Wei
Journal:  Case Rep Hematol       Date:  2019-09-02

10.  Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai, China.

Authors:  Min Liu; Xiangqin Weng; Shenglan Gong; Hui Chen; Jing Ding; Mengqiao Guo; Xiaoxia Hu; Jianmin Wang; Jianmin Yang; Gusheng Tang
Journal:  Oncotarget       Date:  2017-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.